[Leish-l] Publication of Article collection - Immunity against Leishmaniasis: host defences, immunotherapy and vaccines

[egalati at usp.br]

Dear Herbert 

Thank you very much for sending me these articles. They will be very useful for me and my students. 
Sincerely, 
Eunice A B Galati 

----- Mensagem original -----

> De: herbert at biof.ufrj.br
> Para: "Leish-L" <leish-l at lineu.icb.usp.br>
> Enviadas: Sábado, 8 de Outubro de 2016 22:59:26
> Assunto: [Leish-l] Publication of Article collection - Immunity
> against Leishmaniasis: host defences, immunotherapy and vaccines

> Dear colleagues.

> I would like to announce the publication of article collection
> entitled Immunity against Leishmaniasis: host defences, immunotherapy
> and vaccines. See below all manuscripts.

> I would like to thank you so much for all colleagues that participate
> in this collection. Thank you so much!

> Thank you so much Prof. Jeffrey for share this collection with me.

> Hope to have opportunity to work together in the future

> Best regards, Herbert

> Herbert Leonel de Matos Guedes
> Professor, Ph.D.
> Lecturer of Immunology and Parasitology
> Leader the group of Immunology and Vaccinology
> Institute of Biophysics Carlos Chagas Filho
> Federal University of Rio de Janeiro

> Immunity against Leishmaniasis: host defences, immunotherapy and
> vaccines

> http://www.biomedcentral.com/collections/leishmania

> Leishmaniasis is a serious public health problem in both tropical and
> temperate regions, caused by protozoan parasites of the genus
> Leishmania. Over 20 Leishmania species as well as hybrids are
> involved
> and they are transmitted to humans by the bite of infected
> phlebotomine female sandflies. It is principally a zoonotic disease
> and some 70 animal species are reservoirs but, in some regions,humans
> themselves are the source of infection. 1.3 million new cases and 20
> 000 deaths occur annually.

> There are 3 main clinical forms:
> • Cutaneous: the most common form, 95% of the cases occur in the
> Americas, the Mediterranean basin, the Middle East and Central Asia -
> single or disseminated skin lesions
> • Mucocutaneous: principally in the Americas, destruction of mucosal
> regions of the nose, mouth and throat
> • Visceral: the fatal form of disease, the majority of cases occur in
> 6 countries: Bangladesh, Brazil, Ethiopia, India, Sudan and South
> Sudan.

> There are two other important, but less common, forms:
> • Diffuse cutaneous leishmaniasis (DCL): an anergid form of disease -
> rare, America and Oriental Africa
> • Post-kala-azar dermal leishmaniasis (PKDL): endemic in East Africa
> and the Indian subcontinent. A sequela of visceral resolution, there
> is cutaneous manifestation.

> There is a lack of sustainable control measures and different forms
> of
> the disease are expanding. Of particular concern is the increasing
> number of subclinical infections of Leishmania parasites that may
> flare up due to immunosuppression or be a source of infection in
> blood
> transfusions or organ transplants. A key goal is the reduction of
> fatal cases of visceral leishmaniasis in both India and Brazil but
> this is difficult in the absence of a vaccine for humans. Treatment
> in
> lower-income countries is based on toxic medicines developed in the
> 1940s. This is aggravated by the development of resistance to these
> older medications.

> The aim of this collectio is to draw attention to areas of basic and
> applied research that focus on immunity/pathogenesis in the
> development of new therapies and vaccines.

> Guest Editors: Prof. Jeffrey Shaw and Prof. Herbert Leonel de Matos
> Guedes

> 18) Research
> Efficacy of intranasal LaAg vaccine against Leishmania
> amazonensis infection in partially resistant C57Bl/6 mice

> Juliana Elena Silveira Pratti, Tadeu Diniz Ramos, Joyce Carvalho
> Pereira, Alessandra Marcia da Fonseca-Martins, Diogo Maciel-Oliveira,
> Gabriel Oliveira-Silva, Mirian França de Mello, Suzana Passos Chaves,
> Daniel Claudio Oliveira Gomes, Bruno Lourenço Diaz, Bartira
> Rossi-Bergmann and Herbert Leonel de Matos Guedes

> Parasites & Vectors 2016 9:534

> 17) Review
> Differences in immune responses against Leishmania induced by
> infection and by immunization with killed parasite antigen:
> implications for vaccine discovery

> Sergio C. F. Mendonça

> Parasites & Vectors 2016 9:492

> 16) Review
> Crosstalk between purinergic receptors and lipid mediators in
> leishmaniasis

> Mariana M. Chaves, Cláudio Canetti and Robson Coutinho-Silva

> Parasites & Vectors 2016 9:489

> 15) Research
> Multicomponent LBSap vaccine displays immunological and
> parasitological profiles similar to those of Leish-Tec® and
> Leishmune®
> vaccines against visceral leishmaniasis

> Ludmila Zanandreis de Mendonça, Lucilene Aparecida Resende,
> Mariana Ferreira Lanna, Rodrigo Dian de Oliveira Aguiar-Soares, Bruno
> Mendes Roatt, Renata Alves de Oliveira e Castro, Maurício Azevedo
> Batista, Denise Silveira-Lemos, Juliana de Assis Silva Gomes, Ricardo
> Toshio Fujiwara, Simone Aparecida Rezende, Olindo Assis
> Martins-Filho,
> Rodrigo Corrêa-Oliveira, Walderez Ornelas Dutra, Alexandre Barbosa
> Reis and Rodolfo Cordeiro Giunchetti

> Parasites & Vectors 2016 9:472

> 14) Review
> The immunology of post-kala-azar dermal leishmaniasis (PKDL)

> Eduard E. Zijlstra

> Parasites & Vectors 2016 9:464

> 13) Research
> The leishmanicidal activity of oleuropein is selectively
> regulated through inflammation- and oxidative stress-related genes

> Ioannis D. Kyriazis, Olga S. Koutsoni, Nektarios Aligiannis,
> Kalliopi Karampetsou, Alexios-Leandros Skaltsounis and Eleni Dotsika

> Parasites & Vectors 2016 9:441

> 12) Letter to the Editor
> Comment on “Regulation of immunity during visceral Leishmania
> infection” and further discussions about the role of antibodies in
> infections with Leishmania

> Luiz Gustavo Gardinassi and Isabel Kinney Ferreira de Miranda Santos

> Parasites & Vectors 2016 9:386

> 11) Research
> Development of real-time PCR assays for evaluation of immune
> response and parasite load in golden hamster (Mesocricetus auratus)
> infected by Leishmania (Viannia) braziliensis

> Raquel Peralva Ribeiro-Romão, Andrea Franco Saavedra, Alda Maria
> Da-Cruz, Eduardo Fonseca Pinto and Otacilio C. Moreira

> Parasites & Vectors 2016 9:361

> 10) Research
> Insulin-like growth factor-I serum levels and their biological
> effects on Leishmania isolates from different clinical forms of
> American tegumentary leishmaniasis

> Luana Dias de Souza, Célia Maria Vieira Vendrame, Amélia Ribeiro
> de Jesus, Márcia Dias Teixeira Carvalho, Andréa Santos Magalhães,
> Albert Schriefer, Luiz Henrique Guimarães, Edgar Marcelino de
> Carvalho
> and Hiro Goto

> Parasites & Vectors 2016 9:335

> 9) Review
> Possibilities and challenges for developing a successful vaccine
> for leishmaniasis

> Saumya Srivastava, Prem Shankar, Jyotsna Mishra and Sarman Singh

> Parasites & Vectors 2016 9:277

> 8) Review
> The site of the bite: Leishmania interaction with macrophages,
> neutrophils and the extracellular matrix in the dermis

> Juliana Perrone de Menezes, Elvira M. Saraiva and Bruno da
> Rocha-Azevedo

> Parasites & Vectors 2016 9:264

> 7) Research
> Application of rapid in vitro co-culture system of macrophages
> and T-cell subsets to assess the immunogenicity of dogs vaccinated
> with live attenuated Leishmania donovani centrin deleted parasites
> (LdCen−/−)

> Kelvinson Fernandes Viana, Jacqueline Araújo Fiuza, Sreenivas
> Gannavaram, Ranadhir Dey, Angamuthu Selvapandiyan, Daniella
> Castanheira Bartholomeu, Denise da Silveira-Lemos, Lilian Lacerda
> Bueno, Walderez Ornelas Dutra, Ricardo Toshio Fujiwara, Hira L.
> Nakhasi and Rodolfo Cordeiro Giunchetti

> Parasites & Vectors 2016 9:250

> 6) Research
> The sandfly Lutzomyia longipalpis LL5 embryonic cell line has
> active Toll and Imd pathways and shows immune responses to bacteria,
> yeast and Leishmania

> Bruno Tinoco-Nunes, Erich Loza Telleria, Monique da Silva-Neves,
> Christiane Marques, Daisy Aline Azevedo-Brito, André Nóbrega Pitaluga
> and Yara Maria Traub-Csekö

> Parasites & Vectors 2016 9:222

> 5) Research
> Impact of reactive oxygen species (ROS) on the control of
> parasite loads and inflammation in Leishmania amazonensis infection

> Eric Henrique Roma, Juan Pereira Macedo, Grazielle Ribeiro Goes,
> Juliana Lauar Gonçalves, Waldionê de Castro, Daniel Cisalpino and
> Leda
> Quercia Vieira

> Parasites & Vectors 2016 9:193

> 4) Short report
> Imipramine alters the sterol profile in Leishmania amazonensis
> and increases its sensitivity to miconazole

> Valter Viana Andrade-Neto, Thaís Martins Pereira, Marilene do
> Canto-Cavalheiro and Eduardo Caio Torres-Santos

> Parasites & Vectors 2016 9:183

> 3) Research
> Clinical, hematological and biochemical alterations in hamster
> (Mesocricetus auratus) experimentally infected with Leishmania
> infantum through different routes of inoculation

> Nádia das Dores Moreira, Juliana Vitoriano-Souza, Bruno Mendes
> Roatt, Paula Melo de Abreu Vieira, Wendel Coura-Vital, Jamille
> Mirelle
> de Oliveira Cardoso, Mariana Trevisan Rezende, Henrique Gama Ker,
> Rodolfo Cordeiro Giunchetti, Claudia Martins Carneiro and Alexandre
> Barbosa Reis

> Parasites & Vectors 2016 9:181

> 2) Review
> Study of Leishmania pathogenesis in mice: experimental considerations

> Corinne Loeuillet, Anne-Laure Bañuls and Mallorie Hide

> Parasites & Vectors 2016 9:144

> 1) Review
> Regulation of immunity during visceral Leishmania infection

> Vasco Rodrigues, Anabela Cordeiro-da-Silva, Mireille Laforge,
> Ricardo Silvestre and Jérôme Estaquier

> Parasites & Vectors 2016 9:118

> _______________________________________________
> Leish-l mailing list
> Leish-l at lineu.icb.usp.br
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l

> --
> This email was sent by icb.usp.br
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20161010/82e5b24e/attachment.htm>